Prostaglandin E2

规格

363-24-6CAS 号

206-656-6EC 号

(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acidIUPAC 名称

C20H32O5化学式

352.5 g/mol分子量

Prostaglandin E2; Dinoprostone; 363-24-6; PGE2; Prostin E2; Prepidil; Cervidil; Minprostin E2; Propess; Minprositin E2; Dinoproston; Dinoprostonum; Cerviprost; Dinoprostona; Enzaprost E; Cerviprime; Prostenone; PGE2alpha; U-12062; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; Prostaglandin E2alpha; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; DTXSID4022947; U 12062; K7Q1JQR04M; Prostaglandin E(2); (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; NSC-165560; NSC-196514; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; Dinoprostone beta-Cyclodextrin Clathrate; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-; Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,13E,15S)-; DTXCID002947; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; CHEBI:15551; U-12,062; Prosta-5,13-dien-1-oic acid, (5Z,11-alpha,13E,15S)-11,15-dihydroxy-9-oxo-; PGE2 alpha; Prostaglandin E2 alpha; 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-; Gel, Prepidil; E2, Prostaglandin; (Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid; alpha, PGE2; E2alpha, Prostaglandin; alpha, Prostaglandin E2; E2 alpha, Prostaglandin; (E,Z)-(1R,2R,3R)-7-[3-hydroxy-2-[(3S)-(3-hydroxy-1-octenyl)]-5-oxocyclopentyl]-5-heptenoic acid; (Z)-7-((1R,2R,3R)-3-hydroxy-2-((E,3S)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid; RefChem:56458; PGE(2); G02AD02; 9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid; Prostin E2; (Z)-7-((1R,3R)-3-hydroxy-2-((E,3S)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid; 206-656-6; Prostarmon E; (15S)-Prostaglandin E2; l-Prostaglandin E2; Glandin; l-PGE2; (-)-Prostaglandin E2; NSC 165560; Prostaglandin E; (Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid; MFCD00077861; NSC 196514; [3H]PGE2; [3H]prostaglandin E2; Prostaglandin E2 (GMP); CHEMBL548; 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1r,2r,3r)-3-Hydroxy-2-[(E,3s)-3-Hydroxyoct-1-Enyl]-5-Oxo-Cyclopentyl]hept-5-Enoic Acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, l-; (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid; NCGC00092361-05; Prostaglandin E2.alpha.; Dinoprostonum [INN-Latin]; 9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid; Dinoprostona [INN-Spanish]; primiprost; 7-[3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoic acid; Prostarmon E2; Cervidil (TN); Prepidil (TN); CAS-363-24-6; Dinoprostone Prostaglandin E2; U,062; Prostin E2 (TN); PGE2-[3,3,4,4-d4]; SR-05000001459; EINECS 206-656-6; UNII-K7Q1JQR04M; Dinoprostone (JAN/USP/INN); (5Z,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; BML1-F07; Prosta-5, (5Z,11.alpha.,13E,15S)-11,15-dihydroxy-9-oxo-; Prosta-5, 11,15-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-; Prosta-5, 11,5-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-; Dinoprostone CRS; [3H]dinoprostone; prosta-glandin e2; NCGC00092361-06; (E,2R,3R)-7-[3-hydroxy-2-[(3S)-(3-hydroxy-1-octenyl)]-5-oxocyclopentyl]-5-heptenoic acid; Dinoprostone; (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; PGE2; Prestwick_793; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; [3H]prostin E2; BMS-279654 & PGE2; Dinoprostone [USAN:USP:INN:BAN:JAN]; Prostin (prostaglandin); (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; DINOPROSTONE [INN]; DINOPROSTONE [JAN]; DINOPROSTONE [USAN]; (+/-)-Prostaglandin E2; DINOPROSTONE [VANDF]; SCHEMBL25533; BSPBio_001490; DINOPROSTONE [MART.]; Prostaglandin E2 (Standard); DINOPROSTONE [USP-RS]; DINOPROSTONE [WHO-DD]; Prostaglandin E2 (Cervidil)?; PROSTAGLANDIN E2 [MI]; GTPL1883; GTPL1916; orb1302168; Dinoprostone (Prostaglandin E2); [3H]-PGE2; BDBM35847; DTXSID00859353; DINOPROSTONE [ORANGE BOOK]; HMS1361K12; HMS1791K12; HMS1989K12; HMS2089D17; HMS3268J12; HMS3402K12; HMS3413C20; HMS3648F07; HMS3677C20; DINOPROSTONE [EP MONOGRAPH]; DINOPROSTONE [USP IMPURITY]; EX-A1773; MSK15026; P2E; DINOPROSTONE [USP MONOGRAPH]; Tox21_111196; EBC-26697; HB3460; LMFA03010003; NSC165560; NSC196514; s3003; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; AKOS015920228; Tox21_111196_1; AC-6098; CCG-208092; CCG-208256; CS-6932; DB00917; FD31827; HY-101952G; HY-101952R; Alprostadil EP Impurity G; Dinoprostone; IDI1_033960; SMP2_000056; NCGC00092361-01; NCGC00092361-02; NCGC00092361-03; NCGC00092361-04; NCGC00092361-08; AS-71847; SY057971; Dinoprostone 100 microg/mL in Acetonitrile; HY-101952; Prostaglandin E2; Dinoprostone; Prostin E2; ALPROSTADIL IMPURITY G [EP IMPURITY]; CS-0626105; NS00009026; P1884; T5014; C00584; Prostaglandin E2, >=93% (HPLC), synthetic; EN300-22411484; P698583; Q416554; SR-01000946417; SR-01000946417-1; SR-05000001459-1; SR-05000001459-3; SR-05000001459-4; BRD-K26521938-001-04-9; BRD-K26521938-001-07-2; BRD-K26521938-001-09-8; 05D31BD5-818B-4A92-8CFC-BEC19926A5B3; 11alpha,15alpha-Dihydroxy-9-ketoprosta-5,13-dienoic acid; Dinoprostone, European Pharmacopoeia (EP) Reference Standard; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoic acid; (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-5,13-dienoate; 11alpha,15alpha-Dihydroxy-9-oxo-5-cis,13-trans-prostadienoic acid; Dinoprostone, United States Pharmacopeia (USP) Reference Standard; (5Z,11I+/-,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-5,13-dienoic acid; 11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (5Z,11alpha,13E,15S); 5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxo-rosta-5,13-dien-1-oic acid; 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentyl]-5-heptenoic acid; Prostaglandin E2, synthetic, powder, BioReagent, suitable for cell culture; (5Z,11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; 5-Heptenoic acid, 7-[3alpha-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-; Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-; Prostaglandin E2, gamma-irradiated, powder, BioXtra, suitable for cell culture; 22230-04-2同义词